NMPA Draft GMP Annex for Sterile Pharmaceuticals Released – Impact on Overseas Manufacturers

Policy Background and Objectives

On March 17, 2025, the National Medical Products Administration (NMPA) released the “Good Manufacturing Practice (GMP) Annex for Sterile Pharmaceuticals (2010 Revision) (Draft for Comments)” to solicit public input, with a deadline for feedback set for May 30, 2025. This draft introduces updated requirements aimed at enhancing sterile drug quality and safety throughout the production process. The proposed changes will have significant implications for overseas manufacturers, who will need to align their quality systems with these updated standards to ensure continued access to the Chinese market

Key Points of the Draft for Comments

The draft, structured into 12 chapters with 235 articles, details the quality management requirements for the entire production process of sterile pharmaceuticals. Below is an enumeration and elaboration of its main content:

Key Highlights of the Plan

1. Production Environment Control

• Cleanroom Design and Maintenance: Sterile drug production must take place in cleanrooms that meet GMP standards, with designs ensuring air quality and environmental parameters align with sterile production requirements.

• Dynamic Monitoring: Regular monitoring of production environments is required, covering indicators like suspended particles, floating bacteria, and settled bacteria to ensure ongoing environmental stability.

2. Personnel Qualifications and Training

• Qualification Requirements: Key personnel in sterile drug production must possess relevant professional backgrounds and experience to ensure competence in their roles.

• Training Programs: Companies need to develop comprehensive training programs for staff training in sterile operations and quality management, with regular assessments conducted.

3. Production Process Management

• Sterile Operation Standards: Specific requirements for sterile operations are clarified, including personnel attire, operational procedures, and equipment cleaning and disinfection.

• Process Monitoring: Real-time monitoring of production processes is required to ensure all steps meet sterile production standards.

4. Quality Risk Management

• Risk Assessment: Drawing on advanced international quality risk management concepts, companies are required to conduct regular risk assessments to identify potential quality risks.

• Risk Control: Corresponding risk control measures should be formulated based on risk assessment results to ensure drug quality.

5. Supplier Management

• Supplier Audits: Companies must conduct rigorous audits of suppliers to ensure raw material quality meets requirements.

• Quality Agreements: Quality agreements should be signed with suppliers to clarify the responsibilities and obligations of both parties.

6. Document and Record Management

• Document Systems: A robust document management system must be established to ensure all production activities are traceable.

• Record Keeping: Critical data from production processes must be recorded and retained for a minimum of five years.

Key Impacts on Sterile Pharmaceutical Production

The new annex imposes higher requirements on sterile pharmaceutical production, which will significantly impact the industry. Below is a detailed analysis:

1. Enhanced Production Environment

• Cleanroom Upgrades: Companies need to upgrade existing cleanrooms to meet higher environmental control standards.

• Monitoring Equipment Investment: Advanced monitoring equipment must be purchased for real-time production environment surveillance, ensuring stable environmental parameters.

2. Strengthened Personnel Management

• Qualification Certification: Key personnel must obtain qualification certification to ensure they have the professional knowledge and skills for sterile production.

• Training System Optimization: Companies need to refine training systems to ensure staff proficiently master sterile operation skills.

3. Refined Production Process Management

• Process Optimization: The sterile operation process should be optimized to minimize human impact on drug quality.

• Equipment Management: Enhanced maintenance and management of equipment are required to ensure sterile performance.

4. Implementation of Quality Risk Management

• Risk Identification and Assessment: Companies need to establish robust mechanisms for risk identification and assessment to detect potential quality risks promptly.

• Risk Control Measures: Effective risk control measures should be formulated and implemented based on risk assessment results to ensure drug quality.

5. Strengthened Supply Chain Management

• Supplier Audits and Management: Strengthened audits and management of suppliers are necessary to ensure raw material quality meets requirements.

• Quality Traceability Systems: A comprehensive quality traceability system should be established to ensure the quality of raw materials and finished products is traceable.

6. Standardized Document and Record Management

• Document System Development: A comprehensive document system should be established to ensure all production activities are traceable.

• Record Keeping and Management: Enhanced preservation and management of records are required to ensure their completeness and accuracy.

Impacts on Overseas Manufacturers

Overseas manufacturers need to pay special attention to the following:

• Regulatory Alignment and Compliance: Overseas companies must align their quality management systems with the new regulations to avoid product market entry issues due to non-compliance.

• Production Site Inspections: The NMPA may inspect overseas production sites, necessitating thorough preparation by companies to meet GMP requirements.

• Localization of Quality Management Systems: Overseas manufacturers should seek to understand and close an gaps between China local quality management systems to ensure continuing compliance.

Industry Outlook and Corporate Strategies

The implementation of the new regulations will continue the standardized and international development of the sterile pharmaceutical industry in China. Companies are encouraged to adopt the following strategies:

• Facility and Equipment Upgrades: Upgrade production facilities and equipment as required by the new regulations.

• Personnel Training and Capacity Building: Strengthen employee understanding and implementation of the new regulations to ensure the effective operation of quality management systems.

• Supply Chain Management Optimization: Establish closer collaborations with suppliers to ensure raw material quality meets the new regulatory requirements.

China Aligns Sterile GMP with International Standards

The release of the sterile pharmaceutical annex by the NMPA signifies a further alignment of China's pharmaceutical regulatory system with international standards. For overseas manufacturers, this presents both challenges and opportunities. By actively responding to the new regulations, companies can enhance product quality and market competitiveness, better positioning themselves to grasp long-term opportunities in the Chinese market.

Further Information

To read the original NMPA announcement about the draft GMP annex for sterile pharmaceuticals for which opinions are solicited, please click here.

If you are a pharmaceutical manufacturer with questions about how the 2025 NMPA draft GMP Annex for sterile pharmaceuticals may affect your compliance strategy or market access in China, please contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry📚 Request our whitepapers📣 Sign up for our newsletter